AMT-676
Phase 2Small molecule
AMT-676 is one of 89 small molecule programs targeting Colorectal Cancer. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Vectibix
AmgenPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Beyfortus
BeiGenePhase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Bayer Aspirin
BayerPhase 3
Tecentriq
RochePhase 3
Mitosol
UUroGen Pharma Ltd.
Phase 3
Systemic Chemotherapy
SSun Yat-sen University
Phase 3
Intravenous Methylene Blue
CChinese University of Hong Kong
Phase 3
Trodelvy
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMT-676. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMultitude Therapeutics Inc.